Organization
Fred Hutchinson Cancer Center
67 clinical trials
35 abstracts
1 poster
Clinical trial
Allogeneic Hematopoietic Cell Transplantation for Patients With Non-Malignant Disorders Using Treosulfan, Fludarabine, and ThiotepaStatus: Recruiting, Estimated PCD: 2027-07-01
Abstract
Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).Org: UC San Diego Moores Cancer Center, National Cancer Institute/National Institutes of Health, Medical College of Wisconsin and WIN Consortium, Fred Hutchinson Cancer Center, Northwestern University,
Abstract
A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).Org: Fred Hutchinson Cancer Center, University of Washington/Fred Hutchinson Cancer Center,
Abstract
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.Org: Fred Hutchinson Cancer Center, Duke University Health System, Center for Lymphoma, University of Chicago Medical Center, Chicago, IL, Banner MD Anderson Cancer Center,
Abstract
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.Org: City of Hope National Medical Center, Center for International Blood and Marrow Transplant Research, University of North Carolina School of Medicine, Moffitt Cancer Center, Stanford University Hospital,
Abstract
Enhancing prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: A Children’s Oncology Group (COG) report.Org: City of Hope National Medical Center, University of Washington School of Medicine, University of Minnesota, Fred Hutchinson Cancer Center, Seattle Children's Hospital,
Abstract
Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, Boston Children's Hospital, Boston Children's Hospital and Dana-Farber Cancer Institute, St. Jude Children's Research Hospital,
Abstract
Risk of early mortality in patients with cancer experiencing adverse financial events.Org: University of Washington/Fred Hutch Cancer Center, University of Washington School of Medicine, University of Washington, Fred Hutchinson Cancer Center, Fred Hutchinson Cancer Center, Fred Hutchinson Cancer Research Center,
Abstract
Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.Org: Fred Hutchinson Cancer Research Center, University of Michigan, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, Bon Secours Cancer Institute at St. Francis, Cancer & Hematology Centers of Western Michigan,
Clinical trial
Multicenter, Randomized, Open-Label Trial in Children and Adolescents to Establish Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIVStatus: Active (not recruiting), Estimated PCD: 2026-08-31
Abstract
Effects of immune-enhancing nutrition on radical cystectomy outcomes: Primary results from the randomized phase III double-blind clinical trial (S1600).Org: University of Kansas Medical Center, Kansas City, KS, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA,
Abstract
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.Org: Pfizer Inc., Fred Hutchinson Cancer Center, Barts Cancer Institute, University of Colorado Anschutz Medical Campus, Gustave Roussy Cancer Center,
Abstract
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.Org: Orlando Health Cancer Institute, First Department of Medicine, National and Kapodistrian University of Athens, Cooper University Hospital, Norris Comprehensive Cancer Center,
Abstract
Communicating cardiovascular health information and improving coordination with primary care: A Childhood Cancer Survivor Study randomized trial.Org: Fred Hutchinson Cancer Center, St. Jude Children's Research Hospital, University of Washington School of Medicine, Division of Haematology/Oncology, The Hospital for Sick Children, The Hospital for Sick Children,
Abstract
Financial toxicity during pediatric cancer therapy: A qualitative analysis.Org: University of Washington School of Medicine, Seattle Children's Hospital, Fred Hutchinson Cancer Center,
Abstract
Association between financial fragility and treatment patterns in multiple myeloma.Org: Fred Hutchinson Cancer Center, Seattle, WA,
Abstract
Analysis of healthcare provider management of immune-related adverse events and concordance with NCCN Guidelines.Org: Clinical Care Options, LLC, University of Washington School of Medicine, Fred Hutchinson Cancer Center,
Abstract
Inpatient healthcare utilization in the first year following a childhood cancer diagnosis: A population-based analysis.Org: University of Washington School of Medicine, Fred Hutchinson Cancer Center,
Abstract
End of life (EOL) care in head and neck squamous cell carcinoma (HNSCC) compared to other solid tumors (OST) in Washington (WA) State.Org: Fred Hutchinson Cancer Center, Seattle Gummy Company, Wave Life Sciences, Department of Otolaryngology, University of Pittsburgh, Head and Neck Surgery,
Abstract
Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).Org: Mayo Clinic, NYU Langone Health, H. Lee Moffitt Cancer Center and Research Institute, The University of Texas MD Anderson Cancer Center, University of California Irvine,
Abstract
Facilitating adaptive coping with fear of recurrence among breast cancer survivors: Feasibility and acceptability outcomes from a three-arm randomized controlled trial.Org: Indiana University School of Medicine, Fred Hutchinson Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,
Clinical trial
A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune MicroenvironmentStatus: Terminated, Estimated PCD: 2023-03-04
Clinical trial
A Phase I Trial Evaluating Escalating Doses of ²¹¹At-Labeled Anti-CD38 Monoclonal Antibody Followed by HLA-Matched or Haploidentical Donor Hematopoietic Cell Transplantation for High-Risk Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase II Randomized Study to Assess Outcomes With Treosulfan-Based Versus Clofarabine-Based Conditioning in Patients With Myelodysplastic Syndromes With Excess Blasts (MDS-EB), or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)Status: Recruiting, Estimated PCD: 2026-10-03
Clinical trial
A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in ChildrenStatus: Completed, Estimated PCD: 2023-01-30
Clinical trial
A Randomized, Controlled, Phase I Study of Fecal Microbiota Transplant and Dietary Fiber Supplementation in Graft Versus Host DiseaseStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Abstract
Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.Org: Exact Sciences Corporation, CRAB, Rabin Medical Center, Public Health Sciences Division, Department of Breast Medical Oncology,
Abstract
Historic redlining, modern neighborhood structures, and mortality in children, adolescents, and young adults with cancer.Org: University of Washington, Seattle, WA, University of California, San Francisco, San Francisco, CA, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, San Diego State University Department of Biology, San Diego, CA, Fred Hutchinson Cancer Center, Seattle, WA,
Clinical trial
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective StudyStatus: Active (not recruiting), Estimated PCD: 2022-12-28
Clinical trial
A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)Status: , Estimated PCD: 2023-01-13
Clinical trial
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory MelanomaStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in UgandaStatus: Terminated, Estimated PCD: 2023-07-26
Abstract
Hematologic toxicity in 177lu-PSMA-617 treatment for mCRPC: Unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV).Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Division of Hematology & Oncology,
Abstract
Improving the ICAHT grading criteria using time-series clustering.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center,
Abstract
Predictors of severe hematotoxicity after CAR T-cell therapy.Org: University of Washington/Fred Hutchinson Cancer Center, Fred Hutchinson Cancer Center,
Abstract
Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.Org: University of Washington/Fred Hutchinson Cancer Center, Fred Hutchinson Cancer Center,
Abstract
PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of patients with mCRPC with homologous recombination DNA repair deficiency.Org: Fred Hutchinson Cancer Center, Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, University of Washington/Fred Hutch Cancer Center, Department of Laboratory Medicine and Pathology, University of Washington,
Abstract
CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684-003 trial.Org: Fred Hutchinson Cancer Center, University of Washington and Fred Hutchinson Cancer Research Centre, Merck & Co., Inc., Rahway, NJ, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
TRAMP study: A phase 2 trial of tumor necrosis factor-α blockade and AR inhibition in men with CRPC.Org: Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Research Center,
Abstract
EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).Org: A2 Biotherapeutics, Inc., H. Lee Moffitt Cancer Center and Research Institute, Mayo Clinic, NYU Langone Health, New York, NY, Washington University in St. Louis,
Abstract
Hematopoietic stem cell transplant for adults with mixed phenotypic acute leukemia.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center,
Abstract
Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center,
Abstract
Examining laboratory-based VISION eligibility and 177Lu-PSMA-617 outcomes in patients with metastatic castration-resistant prostate cancer.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Division of Hematology & Oncology,
Abstract
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).Org: NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, NSABP Foundation, Inc., UPMC Hillman Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,
Abstract
Patient-reported fatigue and risk of treatment-related adverse events (AEs) in patients receiving systemic therapy in cancer clinical trials.Org: SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Carelon Medical Benefits Management,
Clinical trial
Phase I Study of Autologous Transgenic T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR Tᴍsʟɴ) in Patients With Metastatic Pancreatic Ductal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With MyelofibrosisStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase I/II Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Leukemia or Myelodysplastic Syndrome (MDS)Status: , Estimated PCD: 2025-06-28
Clinical trial
Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2024-10-08
Clinical trial
A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHDStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)Status: Completed, Estimated PCD: 2022-10-26
Clinical trial
A Phase I Study of Adoptive Immunotherapy for Advanced B-Cell Maturation Antigen (BCMA)+ Multiple Myeloma With Autologous CD4+ and CD8+ T Cells Engineered to Express a BCMA-Specific Chimeric Antigen ReceptorStatus: Completed, Estimated PCD: 2021-05-03
Clinical trial
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell TherapyStatus: Recruiting, Estimated PCD: 2027-07-31
Clinical trial
Phase 1 Study of NT-I7 (rhIL-7-hyFc) for the Treatment of Kaposi Sarcoma in Patients With or Without Infection With HIVStatus: Terminated, Estimated PCD: 2023-12-15
Clinical trial
CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Peritransplant Ruxolitinib for Patients With Primary and Secondary MyelofibrosisStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I Single Site Open Label Clinical Trial for the Development of a Human BCG Challenge Model to Assess TB Drugs and Vaccines.Status: Completed, Estimated PCD: 2023-08-23
Clinical trial
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasStatus: Recruiting, Estimated PCD: 2024-11-16
Clinical trial
Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)Status: , Estimated PCD: 2027-10-16
Clinical trial
Acupuncture vs. Standard of Care for Induction Intravesical BCG-Related Adverse Events in High-Risk Non-Muscle Invasive Bladder CancerStatus: Completed, Estimated PCD: 2022-08-16
Clinical trial
Phase 2 Pilot Study to Evaluate Efficacy and Safety of Anakinra to Prevent CD19-Targeted CAR-T Cell-Related Cytokine Release Syndrome (CRS) and Neurotoxicity in Patients With B Cell Lymphoma (B-NHL)Status: Recruiting, Estimated PCD: 2024-10-03
Clinical trial
A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2026-10-11
Clinical trial
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic SclerosisStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Phase 1/2 Dose-Escalation and Cohort Study of STEAP1 CART With Enzalutamide in Participants With mCRPCStatus: Not yet recruiting, Estimated PCD: 2027-03-30
Clinical trial
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure DiseasesStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic DiseasesStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
Rabies Vaccination to Assess Vaccine Responsiveness After B Cell Targeted CAR-T Cell TherapiesStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase 1/2 Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyStatus: Not yet recruiting, Estimated PCD: 2027-10-30
Clinical trial
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and PediatricsStatus: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid NeoplasmStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing CancerStatus: Terminated, Estimated PCD: 2022-08-04
Clinical trial
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological MalignanciesStatus: Terminated, Estimated PCD: 2022-11-11
Clinical trial
A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic LeukemiaStatus: Terminated, Estimated PCD: 2023-03-23
Clinical trial
A Randomized Trial for Patients With High-Grade Myeloid Neoplasms With Measurable Residual Disease (MRD): CPX-351 vs. Immediate Allogeneic Hematopoietic Cell TransplantationStatus: Terminated, Estimated PCD: 2023-08-27
Clinical trial
Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative RegimenStatus: Active (not recruiting), Estimated PCD: 2023-12-22
Clinical trial
A Phase I Trial Evaluating Escalating Doses of 211At-Labeled Anti-CD38 Monoclonal Antibody (211At-OKT10-B10) Combined With Melphalan as Conditioning Prior to Autologous Hematopoietic Cell Transplantation for Patients With Multiple MyelomaStatus: Withdrawn, Estimated PCD: 2025-10-01
Clinical trial
A Phase I Safety and Feasibility Study of Cellular Immunotherapy for Extensive Stage Small Cell Neuroendocrine Prostate Cancer Using Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen ReceptorStatus: Not yet recruiting, Estimated PCD: 2028-03-15
Clinical trial
Acalabrutinib for Chronic Graft-Versus-Host DiseaseStatus: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
A Phase I Study of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells in Combination With JSMD194, a Small Molecule Inhibitor of Gamma Secretase, in Patients With Relapsed or Persistent Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-04-20
Clinical trial
Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MCPyV-Specific TCRs Combined With Avelumab and Class I MHC-Upregulation in Patients With Metastatic MCC Refractory to PD-1 Axis BlockadeStatus: Active (not recruiting), Estimated PCD: 2024-01-10
Clinical trial
Pharmacokinetics of a SARS-CoV-2 Monoclonal Antibody in Hematopoietic Stem Cell Transplant Recipients (COVIDMAB)Status: Terminated, Estimated PCD: 2022-10-18
Clinical trial
Randomized, Placebo-Controlled, Phase II Trial Examining Ustekinumab for Prevention of Graft Vs. Host Disease After Allogeneic Hematopoietic Cell TransplantationStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host DiseaseStatus: Terminated, Estimated PCD: 2023-08-23
Clinical trial
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and SepsisStatus: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
Prevention of Respiratory Viruses Using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study)Status: , Estimated PCD: 2026-07-01
Clinical trial
A Pilot Study of Pembrolizumab and Neoadjuvant Radiation for Large, High-Risk Soft Tissue SarcomasStatus: Completed, Estimated PCD: 2023-06-08
Clinical trial
A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination With CD19-Directed CAR-T Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled TrialStatus: Terminated, Estimated PCD: 2022-12-31
Clinical trial
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Treosulfan Based Preparative RegimenStatus: Completed, Estimated PCD: 2021-12-14
Clinical trial
Randomized Phase II Study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft Versus Host DiseaseStatus: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative RegimenStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors in Participants With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V MutationsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After TransplantationStatus: Terminated, Estimated PCD: 2016-10-01
Clinical trial
Fecal Microbiota Transplantation to Prevent Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell TransplantationStatus: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
Acalabrutinib in Combination With Venetoclax (AV) for Previously Treated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Status: Recruiting, Estimated PCD: 2027-08-10
Clinical trial
Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant DiseasesStatus: , Estimated PCD: 2028-01-09
Clinical trial
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)Status: Terminated, Estimated PCD: 2024-02-15